{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:55:59Z","timestamp":1791564959394,"version":"4.3.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T00:00:00Z","timestamp":1571616000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T00:00:00Z","timestamp":1571616000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["16\/31\/63"],"award-info":[{"award-number":["16\/31\/63"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Patients with functional motor disorder (FMD) experience persistent and disabling neurological symptoms such as weakness, tremor, dystonia and disordered gait. Physiotherapy is usually considered an important part of treatment; however, sufficiently-powered controlled studies are lacking. Here we present the protocol of a randomised controlled trial (RCT) that aims to evaluate the clinical and cost effectiveness of a specialist physiotherapy programme for FMD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods\/design<\/jats:title><jats:p>The trial is a pragmatic, multicentre, single blind parallel arm randomised controlled trial (RCT). 264 Adults with a clinically definite diagnosis of FMD will be recruited from neurology clinics and randomised to receive either the trial intervention (a specialist physiotherapy protocol) or treatment as usual control (referral to a community physiotherapy service suitable for people with neurological symptoms). Participants will be followed up at 6 and 12\u2009months. The primary outcome is the Physical Function domain of the Short Form 36 questionnaire at 12\u2009months. Secondary domains of measurement will include participant perception of change, mobility, health-related quality of life, health service utilisation, anxiety and depression. Health economic analysis will evaluate the cost impact of trial and control interventions from a health and social care perspective as well as societal perspective.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>This trial will be the first adequately-powered RCT of physical-based rehabilitation for FMD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration<\/jats:title><jats:p>International Standard Randomised Controlled Trials Number<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/doi.org\/10.1186\/ISRCTN56136713\">ISRCTN56136713<\/jats:ext-link>. Registered 27 March 2018.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12883-019-1461-9","type":"journal-article","created":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T12:49:47Z","timestamp":1571662187000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Physio4FMD: protocol for a multicentre randomised controlled trial of specialist physiotherapy for functional motor disorder"],"prefix":"10.1186","volume":"19","author":[{"name":"on behalf of the Physio4FMD Collaborative Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6053-5670","authenticated-orcid":false,"given":"Glenn","family":"Nielsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9829-8092","authenticated-orcid":false,"given":"Jon","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4016-5857","authenticated-orcid":false,"given":"Marta","family":"Buszewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7425-0964","authenticated-orcid":false,"given":"Alan","family":"Carson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9387-3035","authenticated-orcid":false,"given":"Laura H.","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Holt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Marsden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9973-1131","authenticated-orcid":false,"given":"Louise","family":"Marston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4267-1609","authenticated-orcid":false,"given":"Hayley","family":"Noble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4104-6705","authenticated-orcid":false,"given":"Markus","family":"Reuber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,21]]},"reference":[{"key":"1461_CR1","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/jamaneurol.2018.1264","volume":"75","author":"AJ Espay","year":"2018","unstructured":"Espay AJ, Aybek S, Carson A, Edwards MJ, Goldstein LH, Hallett M, et al. Current concepts in diagnosis and treatment of functional neurological disorders. JAMA Neurol. 2018;75:1132\u201341. https:\/\/doi.org\/10.1001\/jamaneurol.2018.1264 .","journal-title":"JAMA Neurol"},{"key":"1461_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00415-011-6111-0","volume":"259","author":"J Stone","year":"2012","unstructured":"Stone J, Carson A, Duncan R, Roberts R, Coleman R, Warlow C, et al. Which neurological diseases are most likely to be associated with \u201csymptoms unexplained by organic disease\u201d. J Neurol. 2012;259:33\u20138.","journal-title":"J Neurol"},{"key":"1461_CR3","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1002\/mds.25544","volume":"28","author":"I Parees","year":"2013","unstructured":"Parees I, Saifee TA, Kojovic M, Kassavetis P, Rubio-Agusti I, Sadnicka A, et al. Functional (psychogenic) symptoms in Parkinson\u2019s disease. Mov Disord. 2013;28:1622\u20137. https:\/\/doi.org\/10.1002\/mds.25544 .","journal-title":"Mov Disord"},{"key":"1461_CR4","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/B978-0-12-801772-2.00005-9","volume-title":"Functional neurologic disorders, Vol 139 of the handbook of clinical neurology series","author":"A Carson","year":"2016","unstructured":"Carson A, Lehn A. Epidemiology. In: Hallett M, Stone J, Carson A, editors. Functional neurologic disorders, Vol 139 of the handbook of clinical neurology series. Amsterdam: Elsevier; 2016. p. 47\u201360."},{"key":"1461_CR5","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1136\/jnnp-2013-305321","volume":"85","author":"J Gelauff","year":"2014","unstructured":"Gelauff J, Stone J, Edwards MJ, Carson A. The prognosis of functional (psychogenic) motor symptoms: a systematic review. J Neurol Neurosurg Psychiatry. 2014;85:220\u20136.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1461_CR6","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jpsychores.2013.05.006","volume":"75","author":"G Nielsen","year":"2013","unstructured":"Nielsen G, Stone J, Edwards MJ. Physiotherapy for functional (psychogenic) motor symptoms: a systematic review. J Psychosom Res. 2013;75:93\u2013102. https:\/\/doi.org\/10.1016\/j.jpsychores.2013.05.006 .","journal-title":"J Psychosom Res"},{"key":"1461_CR7","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.parkreldis.2011.10.011","volume":"18","author":"K Czarnecki","year":"2012","unstructured":"Czarnecki K, Thompson JM, Seime R, Geda YE, Duffy JR, Ahlskog JE. Functional movement disorders: successful treatment with a physical therapy rehabilitation protocol. Park Relat Disord. 2012;18:247\u201351. https:\/\/doi.org\/10.1016\/j.parkreldis.2011.10.011 .","journal-title":"Park Relat Disord"},{"key":"1461_CR8","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/mds.22952","volume":"25","author":"C Dallocchio","year":"2010","unstructured":"Dallocchio C, Arbasino C, Klersy C, Marchioni E. The effects of physical activity on psychogenic movement disorders. Mov Disord. 2010;25:421\u20135. https:\/\/doi.org\/10.1002\/mds.22952 .","journal-title":"Mov Disord"},{"key":"1461_CR9","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1007\/s00415-014-7631-1","volume":"262","author":"G Nielsen","year":"2015","unstructured":"Nielsen G, Ricciardi L, Demartini B, Hunter R, Joyce E, Edwards MJ. Outcomes of a 5-day physiotherapy programme for functional (psychogenic) motor disorders. J Neurol. 2015;262:674\u201381. https:\/\/doi.org\/10.1007\/s00415-014-7631-1 .","journal-title":"J Neurol"},{"key":"1461_CR10","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/mdc3.12325","volume":"28","author":"A Matthews","year":"2016","unstructured":"Matthews A, Brown M, Stone J. Inpatient physiotherapy for functional (psychogenic) gait disorder: a case series of 35 patients. Mov Disord Clin Pract. 2016;28:93\u20136. https:\/\/doi.org\/10.1002\/mdc3.12325 .","journal-title":"Mov Disord Clin Pract"},{"key":"1461_CR11","doi-asserted-by":"publisher","first-page":"181","DOI":"10.2340\/16501977-1246","volume":"46","author":"AA Jordbru","year":"2014","unstructured":"Jordbru AA, Smedstad LM, Klungs\u00f8yr O, Martinsen EW. Psychogenic gait disorder: a randomized controlled trial of physical rehabilitation with one-year follow-up. J Rehabil Med. 2014;46:181\u20137.","journal-title":"J Rehabil Med"},{"key":"1461_CR12","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1136\/jnnp-2016-314408","volume":"88","author":"G Nielsen","year":"2017","unstructured":"Nielsen G, Buszewicz M, Stevenson F, Hunter R, Holt K, Dudziec M, et al. Randomised feasibility study of physiotherapy for patients with functional motor symptoms. J Neurol Neurosurg Psychiatry. 2017;88:484\u201390. https:\/\/doi.org\/10.1136\/jnnp-2016-314408 .","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1461_CR13","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1136\/jnnp-2014-309255","volume":"86","author":"G Nielsen","year":"2015","unstructured":"Nielsen G, Stone J, Matthews A, Brown M, Sparkes C, Farmer R, et al. Physiotherapy for functional motor disorders: a consensus recommendation. J Neurol Neurosurg Psychiatry. 2015;86:1113\u20139. https:\/\/doi.org\/10.1136\/jnnp-2014-309255 .","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1461_CR14","doi-asserted-by":"publisher","first-page":"a1655","DOI":"10.1136\/bmj.a1655","volume":"337","author":"P Craig","year":"2008","unstructured":"Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M. Developing and evaluating complex interventions: the new Medical Research Council guidance. BMJ. 2008;337:a1655 http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=2769032&tool=pmcentrez&rendertype=abstract . Accessed 19 Mar 2016.","journal-title":"BMJ"},{"key":"1461_CR15","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1097\/WCO.0b013e32832dc169","volume":"22","author":"A Gupta","year":"2009","unstructured":"Gupta A, Lang AE. Psychogenic movement disorders. Curr Opin Neurol. 2009;22:430\u20136. https:\/\/doi.org\/10.1097\/WCO.0b013e32832dc169 .","journal-title":"Curr Opin Neurol"},{"key":"1461_CR16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1136\/practneurol-2015-001241","volume":"16","author":"J Stone","year":"2016","unstructured":"Stone J. Functional neurological disorders: the neurological assessment as treatment. Pr Neurol. 2016;16:7\u201317.","journal-title":"Pr Neurol"},{"key":"1461_CR17","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1097\/WCO.0b013e3283633953","volume":"26","author":"MJ Edwards","year":"2013","unstructured":"Edwards MJ, Fotopoulou A, Parees I. Neurobiology of functional (psychogenic) movement disorders. Curr Opin Neurol. 2013;26:442\u20137. https:\/\/doi.org\/10.1097\/WCO.0b013e3283633953 .","journal-title":"Curr Opin Neurol"},{"issue":"11","key":"1461_CR18","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1093\/brain\/aws129","volume":"135","author":"MJ Edwards","year":"2012","unstructured":"Edwards MJ, Adams RA, Brown H, Parees I, Friston KJ. A Bayesian account of \u201chysteria\u201d. Brain. 2012;135(11):3495\u2013512. https:\/\/doi.org\/10.1093\/brain\/aws129 .","journal-title":"Brain"},{"key":"1461_CR19","doi-asserted-by":"publisher","unstructured":"Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. https:\/\/doi.org\/10.1136\/bmj.g1687 .","DOI":"10.1136\/bmj.g1687"},{"key":"1461_CR20","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/BF00647843","volume":"3","author":"C Jenkinson","year":"1994","unstructured":"Jenkinson C, Wright L, Coulter A. Criterion validity and reliability of the SF-36 in a population sample. Qual Life Res. 1994;3:7\u201312.","journal-title":"Qual Life Res"},{"key":"1461_CR21","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s12603-009-0010-4","volume":"13","author":"HE Syddall","year":"2009","unstructured":"Syddall HE, Martin HJ, Harwood RH, Cooper C, Aihie Sayer A. The SF-36: a simple, effective measure of mobility-disability for epidemiological studies. J Nutr Health Aging. 2009;13:57\u201362.","journal-title":"J Nutr Health Aging"},{"key":"1461_CR22","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1097\/01241398-200409000-00011","volume":"24","author":"HK Graham","year":"2004","unstructured":"Graham HK, Harvey A, Rodda J, Nattrass GR, Pirpiris M. The functional mobility scale (FMS). J Pediatr Orthop. 2004;24:514\u201320.","journal-title":"J Pediatr Orthop"},{"key":"1461_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/08870440290001494","volume":"16","author":"R Moss-Morris","year":"2002","unstructured":"Moss-Morris R, Weinman J, Petrie KJ, Horne R, Cameron LD, Buick D. The revised illness perception questionnaire (IPQ-R). Psychol Health. 2002;16:1\u201316.","journal-title":"Psychol Health"},{"key":"1461_CR24","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","volume":"67","author":"AS Zigmond","year":"1983","unstructured":"Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361\u201370.","journal-title":"Acta Psychiatr Scand"},{"key":"1461_CR25","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1212\/WNL.0b013e318228c0c7","volume":"77","author":"M Sharpe","year":"2011","unstructured":"Sharpe M, Walker J, Williams C, Stone J, Cavanagh J, Murray G, et al. Guided self-help for functional (psychogenic) symptoms: a randomized controlled efficacy trial. Neurology. 2011;77:564\u201372.","journal-title":"Neurology"},{"key":"1461_CR26","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jval.2014.09.004","volume":"18","author":"Y Yang","year":"2015","unstructured":"Yang Y, Rowen D, Brazier J, Tsuchiya A, Young T, Longworth L. An exploratory study to test the impact on three \u201cbolt-on\u201d items to the EQ-5D. Value Health. 2015;18:52\u201360. https:\/\/doi.org\/10.1016\/j.jval.2014.09.004 .","journal-title":"Value Health"},{"key":"1461_CR27","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20:1727\u201336.","journal-title":"Qual Life Res"},{"key":"1461_CR28","doi-asserted-by":"crossref","unstructured":"Chisholm D, Knapp MR, Knudsen HC, Amaddeo F, Gaite L, van Wijngaarden B. Client socio-demographic and service receipt inventory--European version: development of an instrument for international research. EPSILON study 5. European psychiatric services: inputs linked to outcome domains and needs. Br J Psychiatry Suppl. 2000:s28\u201333 http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10945075 . Accessed 1 Apr 2016.","DOI":"10.1192\/bjp.177.39.s28"},{"key":"1461_CR29","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/JOM.0b013e3182029110","volume":"53","author":"J Lenneman","year":"2011","unstructured":"Lenneman J, Schwartz S, Giuseffi DL, Wang C. Productivity and health: an application of three perspectives to measuring productivity. J Occup Environ Med. 2011;53:55\u201361. https:\/\/doi.org\/10.1097\/JOM.0b013e3182029110 .","journal-title":"J Occup Environ Med"},{"key":"1461_CR30","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12883-015-0350-0","volume":"15","author":"LH Goldstein","year":"2015","unstructured":"Goldstein LH, Mellers JDC, Landau S, Stone J, Carson A, Medford N, et al. COgnitive behavioural therapy vs standardised medical care for adults with dissociative non-epileptic seizures (CODES): a multicentre randomised controlled trial protocol. BMC Neurol. 2015;15:98. https:\/\/doi.org\/10.1186\/s12883-015-0350-0 .","journal-title":"BMC Neurol"},{"key":"1461_CR31","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1097\/00006842-200203000-00008","volume":"64","author":"K Kroenke","year":"2002","unstructured":"Kroenke K, Spitzer RL, Williams JBW. The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. Psychosom Med. 2002;64:258\u201366.","journal-title":"Psychosom Med"},{"key":"1461_CR32","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1136\/jnnp-2014-308234","volume":"86","author":"AJ Carson","year":"2015","unstructured":"Carson AJ, Stone J, Hansen CH, Duncan R, Cavanagh J, Matthews K, et al. Somatic symptom count scores do not identify patients with symptoms unexplained by disease: a prospective cohort study of neurology outpatients. J Neurol Neurosurg Psychiatry. 2015;86:295\u2013301.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1461_CR33","unstructured":"SealedEnvelope. Randomisation and online databases for clinical trials. https:\/\/www.sealedenvelope.com\/ . Accessed 26 Jun 2019."},{"key":"1461_CR34","doi-asserted-by":"publisher","DOI":"10.22024\/UniKent\/01.02\/65559","volume-title":"Unit costs of health and social care 2017. Personal Social Services Research Unit","author":"LA Curtis","year":"2017","unstructured":"Curtis LA, Burns A. Unit costs of health and social care 2017. Personal Social Services Research Unit. Canterbury: University of Kent; 2017. https:\/\/doi.org\/10.22024\/UniKent\/01.02\/65559 ."},{"key":"1461_CR35","unstructured":"Joint Formulary Committee. British National Formulary (online) London: BMJ Group and Pharmaceutical Press. http:\/\/www.medicinescomplete.com . Accessed 4 Jul 2019."},{"key":"1461_CR36","unstructured":"NHS Improvement. Reference costs. 2017. https:\/\/improvement.nhs.uk\/resources\/reference-costs\/ . Accessed 19 Jan 2018."},{"key":"1461_CR37","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMra1510059","volume":"375","author":"I Ford","year":"2016","unstructured":"Ford I, Norrie J. Pragmatic trials. N Engl J Med. 2016;375:454\u201363. https:\/\/doi.org\/10.1056\/NEJMra1510059 .","journal-title":"N Engl J Med"},{"key":"1461_CR38","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/mdc3.12475","volume":"4","author":"G Nielsen","year":"2017","unstructured":"Nielsen G, Ricciardi L, Meppelink A, Holt K, Teodoro T, Edwards MJ. A simplified version of the psychogenic movement disorders rating scale: the simplified functional movement disorders rating scale (S-FMDRS). Mov Disord Clin Pract. 2017;4:710\u20136.","journal-title":"Mov Disord Clin Pract"},{"key":"1461_CR39","volume-title":"Outcome measures for functional neurological (conversion) disorder. A review of the theoretical complexities. Submitted","author":"T Nicholson","year":"2019","unstructured":"Nicholson T, Carson A, Edwards MJ, Goldstein L, Hallett M, Mildon B, et al. Outcome measures for functional neurological (conversion) disorder. A review of the theoretical complexities. Submitted. 2019."}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-019-1461-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12883-019-1461-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-019-1461-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,25]],"date-time":"2021-01-25T16:30:18Z","timestamp":1611592218000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-019-1461-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,21]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1461"],"URL":"https:\/\/doi.org\/10.1186\/s12883-019-1461-9","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,21]]},"assertion":[{"value":"18 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval was granted from the London-Surrey Borders Research Ethics Committee on 28 March 2018, reference number 18\/LO\/0486. Local NHS approvals are being obtained prior to opening each trial site. Written, informed consent is obtained from each participant prior to undertaking any trial activities.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Glenn Nielsen receives research funding from the National Institute for Health Research. Marta Buszewicz receives research funding from the National Institute of Health Research. Alan Carson acknowledges submitting paid testimony in court actions on a range of neuropsychiatric topics, receiving payment as editor of Journal of Neurology Neurosurgery and Psychiatry, royalties from BMJ press and Elsevier for books and he is the unpaid treasurer of the Functional Neurological Disorder Society. Mark Edwards has received research funding from the Medical Research Council, National Institute for Health Research, and the Guarantors of Brain; honoraria from Merz Pharma, TEVA, and UCB; and publishing royalties from Oxford University Press. Laura Goldstein receives publishing royalties from Wiley and Routledge. Rachael Hunter receives research funding from the National Institute for Health Research. Jonathan Marsden receives research funding from the National Institute for Health Research. Louise Marston receives research funding from the National Institute for Health Research. Markus Reuber receives payment as Editor in Chief of Seizure: European Journal of Epilepsy; royalties from Oxford University Press; an unrestricted research grant from UCB; and speaker fees from Eisai, Livanova, and UCB. Jon Stone receives royalties from UpToDate Inc. and acknowledges paid testimony as an expert witness in court in relation to functional neurological disorders. He is supported by NHS Scotland Career Fellowship and runs the free websitefor patients with functional neurological disorders.None of the other authors have competing interests to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"242"}}